Belinda Lovelace

f2g inc

H指数:13

被引数:590

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Duration of Antifungal Therapy in Disseminated Coccidioidomycosis Patients: A Real-World Treatment Utilization Study

播散性球孢子菌病患者的抗真菌治疗持续时间：一项真实世界治疗利用研究

Journal of Fungi

IF4

2026-04-200

Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis

Mycopathologia

IF2.9

2026-01-130

OAAI

Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis

三唑类药物与钙调磷酸酶或哺乳动物雷帕霉素靶蛋白抑制剂在合并侵袭性曲霉病的实体器官移植住院患者中的联合给药

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2025-12-010

PRE

Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data

曲霉菌病相关死亡率在美国：死亡证明数据分析

CLINICAL INFECTIOUS DISEASES

IF7.3

2025-12-010

PRE

Coccidioidomycosis-Attributable Death in the United States: An Analysis of Cases Reported on Death Certificates, 2018–2023

球孢子菌病相关死亡在美国：对2018-2023年死亡证明上报告病例的分析

Journal of Fungi 2025, Vol. 11, Page 766

IF0

2025-10-240

OAAI

Misuse of the unspecified coccidioidomycosis diagnosis code: An audit of electronic health records

未指定球孢子菌病诊断代码的误用：电子健康记录的审计

MEDICAL MYCOLOGY

IF2.3

2025-10-010

PRE

Healthcare Resource Utilization, Treatment Costs, and Mortality in Patients with Malignancies or Transplantation Who Develop Invasive Aspergillosis

医疗资源利用、治疗费用及死亡率：侵袭性曲霉病在恶性肿瘤或移植患者中的发生情况

Journal of Fungi 2025, Vol. 11, Page 657

IF4

2025-09-060

Antifungal therapy patterns, healthcare utilization, costs, and mortality in central nervous system and non-central nervous system disseminated coccidioidomycosis across the continuum-of-care

抗真菌治疗模式、医疗资源利用、成本及死亡率：中枢神经系统与非中枢神经系统播散性球孢子菌病的全程管理研究

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2025-02-010

PRE

Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2024-12-201

OAAI

Burden of Hospitalization for Coccidioidal Meningitis: An Analysis of the National Inpatient Sample, 2019-2021

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2024-11-271

OAAI

Reply to Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS

IF3.4

2024-05-010

OAAI

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a US hospital-based observational study

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS

IF3.4

2023-08-0122

OAAI

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

CRITICAL CARE

IF9.3

2022-06-1643

OAAI

Derivation And Validation Of The SAVED 2 Score For Prediction Of Unfavorable Modified Rankin Scale Score Following Intracerebral Hemorrhage

STROKE

IF8.9

2022-02-010

PRE

Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA

ADVANCES IN THERAPY

IF4

2020-07-228

PREAI

Belinda Lovelace

个人简介

教育背景

工作经历

荣誉奖项

研究方向